Iovance price target raised to $24 from $22 at B. Riley FBR. B. Riley FBR analyst Madhu Kumar raised his price target for Iovance Biotherapeutics to $24 following last night’s Q1 results. The analyst believes FDA interactions in Q3 could set an approval path for melanoma TILs. He reiterates a Buy rating on the shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.